CLRB – cellectar biosciences, inc. (US:NASDAQ)
Stock Stats
News
12/20
02:03 am
clrb
Low
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/16
10:55 am
clrb
Low
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials [Yahoo! Finance]
12/11
12:54 pm
clrb
Low
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
12/10
05:00 pm
clrb
High
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
12/5
09:05 am
clrb
Medium
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $13.00 price target on the stock.
11/18/2024
07:05 am
CLRB
-11.1%
MISS
5/14/2024
06:40 am
CLRB
2.6%
MISS
12/11
12:54 pm
Reiterates
Outperform
Market Perform
Oppenheimer Holdings Inc.
Low
1.3%
12/11
12:47 pm
Downgrades
Outperform
Perform
Oppenheimer
Low
0.9%
12/11
12:47 pm
Downgrades
Outperform
Perform
Oppenheimer
Low
0.9%
12/11
08:47 am
Downgrades
OUTPERFORM
PERFORM
OPPENHEIMER
High
-38.5%
12/11
08:47 am
Downgrades
OUTPERFORM
PERFORM
OPPENHEIMER
High
-38.5%
12/11
09:05 am
clrb
High
Form 8-K Cellectar Biosciences, For: Dec 10
11/18
07:15 am
clrb
High
Form 8-K Cellectar Biosciences, For: Nov 18
11/18
06:46 am
clrb
Medium
Form 10-Q Cellectar Biosciences, For: Sep 30
11/15
04:34 pm
clrb
Medium
Form 8-K Cellectar Biosciences, For: Nov 15
11/14
04:55 pm
clrb
Medium
Form SCHEDULE 13G/A Cellectar Biosciences, Filed by: Nantahala Capital Management, LLC
Show more
Top News Gainers
12/10 Cellectar Biosciences Inc (NASDAQ: CLRB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock. 17.5%
12/2 Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference 15.7%
5/15 CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma 11.5%
1/9 Form 8-K Cellectar Biosciences, For: Jan 09 8.9%
5/28 Form SC 13G Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 8.8%
10/15 Form 8-K Cellectar Biosciences, For: Oct 15 8.1%
2/14 Form SC 13G/A Cellectar Biosciences, Filed by: TANG CAPITAL PARTNERS LP 7.5%
1/3 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.75 price target on the stock. 7.0%
2/25 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.6%
12/19 Cellectar Biosciences to Present at Biotech Showcase 2020 5.9%
Top News Decliners
7/9 Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma -26.9%
5/15 Form 8-K Cellectar Biosciences, For: May 15 -23.0%
2/19 Cellectar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study -20.9%
9/24 Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma -17.5%
11/12 Form 8-K Cellectar Biosciences, For: Nov 12 -14.7%
5/13 Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma -12.6%
2/20 Form 8-K Cellectar Biosciences, For: Feb 19 -11.9%
3/17 Cellectar Biosciences Inc (NASDAQ: CLRB) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
3/9 Cellectar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update -7.9%
3/10 Cellectar Biosciences Inc (NASDAQ: CLRB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3